Verity Drug Patent Portfolio
Verity owns 2 orange book drugs protected by 15 US patents Given below is the list of Verity's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11464735 | Fixed dose oral testosterone undecanoate compositions and use thereof | 28 Apr, 2041 | Active |
| US12011503 | Fixed dose oral testosterone undecanoate compositions and use thereof | 16 Oct, 2040 | Active |
| US11559530 | Oral testosterone undecanoate therapy | 28 Nov, 2037 | Active |
| US10226473 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US10716794 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US11311555 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US11364249 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US11433083 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US9943527 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US9949985 | High-strength testosterone undecanoate compositions | 30 Nov, 2030 | Active |
| US10166181 | Slow release pharmaceutical composition made of microgranules | 30 Jun, 2029 | Active |
| US11304960 | Steroidal compositions | 08 Jan, 2029 | Active |
| US8778922 | Steroidal compositions | 08 Jan, 2029 | Active |
| US8865695 | Steroidal compositions | 08 Jan, 2029 | Active |
| US5776885 | Sustained and controlled release of water insoluble polypeptides | 07 Jul, 2015 | Expired |
Latest Legal Activities on Verity's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Verity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Mar, 2023 | US10226473 |
| Surcharge for late Payment, Small Entity | 09 Mar, 2023 | US10226473 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2023 | US11559530 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jan, 2023 | US11559530 |
|
Correspondence Address Change
Critical
| 09 Jan, 2023 | US11464735 |
|
Email Notification
Critical
| 05 Jan, 2023 | US11559530 |
|
Issue Notification Mailed
Critical
| 04 Jan, 2023 | US11559530 |
| Mail Miscellaneous Communication to Applicant | 28 Dec, 2022 | US11559530 |
|
Email Notification
Critical
| 28 Dec, 2022 | US11559530 |
| Miscellaneous Communication to Applicant - No Action Count | 22 Dec, 2022 | US11559530 |
|
Application Is Considered Ready for Issue
Critical
| 21 Dec, 2022 | US11559530 |
| Dispatch to FDC | 21 Dec, 2022 | US11559530 |
| Request for Refund | 19 Dec, 2022 | US11559530 |
|
Email Notification
Critical
| 16 Dec, 2022 | US11559530 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Dec, 2022 | US11559530 |
Verity Drug Patents' Oppositions Filed in EPO
Verity drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12172232A | Apr, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP08763237A | Sep, 2017 | Ferring B.V. | Revoked |
| EP08763237A | Sep, 2017 | Generics (UK) Ltd | Revoked |
Verity's Family Patents
Verity Drug List
Given below is the complete list of Verity's drugs and the patents protecting them.
1. Tlando
Tlando is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11464735 | Fixed dose oral testosterone undecanoate compositions and use thereof |
28 Apr, 2041
(16 years from now)
| Active |
| US12011503 | Fixed dose oral testosterone undecanoate compositions and use thereof |
16 Oct, 2040
(15 years from now)
| Active |
| US11559530 | Oral testosterone undecanoate therapy |
28 Nov, 2037
(13 years from now)
| Active |
| US10226473 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US10716794 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US11311555 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US11364249 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US11433083 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US9943527 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US9949985 | High-strength testosterone undecanoate compositions |
30 Nov, 2030
(6 years from now)
| Active |
| US11304960 | Steroidal compositions |
08 Jan, 2029
(4 years from now)
| Active |
| US8778922 | Steroidal compositions |
08 Jan, 2029
(4 years from now)
| Active |
| US8865695 | Steroidal compositions |
08 Jan, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tlando's drug page
2. Trelstar
Trelstar is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166181 | Slow release pharmaceutical composition made of microgranules |
30 Jun, 2029
(4 years from now)
| Active |
| US5776885 | Sustained and controlled release of water insoluble polypeptides |
07 Jul, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trelstar's drug page